Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNMD Stock Price Chart Interactive Chart >
MNMD Price/Volume Stats
| Current price | $2.91 | 52-week high | $19.95 |
| Prev. close | $2.88 | 52-week low | $2.12 |
| Day low | $2.82 | Volume | 239,200 |
| Day high | $2.93 | Avg. volume | 530,770 |
| 50-day MA | $3.45 | Dividend yield | N/A |
| 200-day MA | $5.78 | Market Cap | 110.76M |
Mind Medicine (MindMed) Inc. (MNMD) Company Bio
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest MNMD News From Around the Web
Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
MindMed Reports Full Year 2022 Financial Results and Business HighlightsNEW YORK, March 09, 2023--Mind Medicine (MindMed) Inc. today reported its financial results for the full-year ended December 31, 2022. |
MindMed to Participate in March Investor ConferencesNEW YORK, February 28, 2023--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: |
Nasdaq Gets a Healthy Dose of Psychedelics With Lucy ScientificBy Exec Edge Editorial Staff Lucy Scientific Discovery Inc. (Nasdaq: LSDI), which focuses on psychotropic drugs and had its initial public offering last week, rang the closing bell at the Nasdaq stock exchange today in New York. The company is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines […] |
The 7 Most Promising Psychedelic Stocks to Buy in FebruaryThese psychedelics stocks to buy belong to pre-revenue firms which could potentially blow-up in line with the burgeoning sector. |
Trippy Trading: Top Psychedelic Stocks For 2023When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie... |
MNMD Price Returns
| 1-mo | -20.49% |
| 3-mo | N/A |
| 6-mo | -52.45% |
| 1-year | -83.56% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 32.27% |
| 2022 | -89.37% |
| 2021 | -54.75% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...